Valuation: Altimmune, Inc.

Market Cap 546M 479M 443M 407M 768M 52.7B 781M 5.29B 2.08B 25.78B 2.05B 2.01B 88.83B P/E 2026 *
-4.18x
P/E 2027 * -3.71x
Enterprise Value 163M 143M 132M 122M 230M 15.76B 233M 1.58B 621M 7.71B 614M 600M 26.57B EV / Sales 2026 *
39,863x
EV / Sales 2027 * -
Free-Float
99.59%
Yield 2026 *
-
Yield 2027 * -
1 day-2.09%
1 week-6.02%
Current month-7.57%
1 month+4.07%
3 months-21.07%
6 months-33.57%
Current year-22.16%
1 week 2.77
Extreme 2.77
3
1 month 2.74
Extreme 2.74
3.4
Current year 2.56
Extreme 2.56
6.44
1 year 2.56
Extreme 2.56
6.44
3 years 2.09
Extreme 2.09
14.84
5 years 2.09
Extreme 2.09
23.49
10 years 1.51
Extreme 1.51
237.3
Manager TitleAgeSince
Chief Executive Officer 58 01/01/2026
Director of Finance/CFO 70 11/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2025
Director TitleAgeSince
Director/Board Member 58 01/09/2003
Chairman 78 01/01/2018
Director/Board Member 76 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
01/05/26 Free

Director

48,800 0.0251%
01/05/26 Free

Director

48,800 0.0251%
01/05/26 Free

Director

48,800 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
-2.09%-6.02%-31.13%-11.64% 558M
+0.21%-0.79%+53.17%+57.39% 53.83B
+5.37%+3.31%+50.39%+83.65% 52.1B
-1.20%-1.94%+4.35%+402.68% 23.48B
+0.74%+2.32%-16.23%-14.44% 23.13B
+0.16%+0.31%+36.86%-5.85% 19.36B
-1.18%-2.97%+30.12%-33.30% 17.56B
-1.67%-6.00%+163.95%+284.69% 15.2B
-0.79%+0.46%+32.55%+571.81% 14.83B
-0.70%-0.91%+24.87%+179.47% 14.06B
Average -0.10%-2.03%+34.89%+151.45% 23.41B
Weighted average by Cap. +0.92%-1.51%+41.71%+133.24%

Financials

2026 *2027 *
Net sales 4.1K 3.59K 3.32K 3.06K 5.76K 395K 5.86K 39.72K 15.57K 193K 15.4K 15.06K 666K -
Net income -112M -97.98M -90.57M -83.3M -157M -10.78B -160M -1.08B -425M -5.27B -420M -411M -18.17B -139M -122M -113M -104M -196M -13.42B -199M -1.35B -529M -6.57B -523M -511M -22.63B
Net Debt -383M -336M -310M -285M -539M -36.94B -547M -3.71B -1.45B -18.07B -1.44B -1.41B -62.27B -256M -224M -207M -191M -360M -24.68B -366M -2.48B -972M -12.08B -961M -940M -41.61B
Logo Altimmune, Inc.
Altimmune, Inc. is a late clinical-stage biopharmaceutical company. The Company is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. It has completed phase II development of pemvidutide. It also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
Employees
57
Date Price Change Volume
20/07/26 $2.810 -2.09% 2,614,125
17/07/26 $2.870 +0.70% 2,963,768
16/07/26 $2.850 -4.36% 2,995,414
15/07/26 $2.980 +1.71% 2,862,398
14/07/26 $2.930 -2.01% 3,298,979
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
2.810USD
Average target price
15.45USD
Spread / Average Target
+449.82%

Quarterly revenue - Rate of surprise